The Role of Matrix Metalloproteinases on the Primary Teeth Pulpotomy Treatments
Reversible Pulpitis
About this trial
This is an interventional treatment trial for Reversible Pulpitis focused on measuring MTA, Biodentine, Pulpotomy, Matrix metalloproteinase
Eligibility Criteria
Inclusion Criteria:
- Cooperative pediatric patients aged 5-10 years,
- Deep carious lesion in mandibular primary second molars,
- The subjects did not receive any antiinflammatory medication 3 months prior to the study,
- Feasible restorative treatment,
- Positive parental informed consent.
Exclusion Criteria:
- Uncooperative children,
- Children with medically compromised disease,
- Presence of pathological root resorption and/or bone defect,
- Physiological root resorption more than one-third of the root,
- Unrestorable teeth,
- Negative parental informed consent.
Sites / Locations
- Ege University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis
Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments
The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.